Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Emisphere Development Update
ROSELAND, N.J. , June 29, 2018 (GLOBE NEWSWIRE) -- Novo Nordisk announced yesterday the completion and results of the phase 3a trial, PIONEER 3, with oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analog for the treatment of Type 2 diabetes, which utilizes Emisphere
View HTML
Toggle Summary Emisphere Development Update
ROSELAND, N.J. , June 21, 2018 (GLOBE NEWSWIRE) -- Novo Nordisk announced yesterday the completion and results of the phase 3a trials, PIONEER 4 and 7, with oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analog for the treatment of Type 2 diabetes, which utilizes Emisphere
View HTML
Toggle Summary Emisphere Development Update
ROSELAND, N.J. , May 31, 2018 (GLOBE NEWSWIRE) -- Novo Nordisk (NYSE:NVO) announced Tuesday the completion of the second phase 3a trial, PIONEER 2, with oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analog for the treatment of Type 2 diabetes, which utilizes Emisphere
View HTML
Toggle Summary ELIGEN B12 Receives “Amazon’s Choice” Designation
ROSELAND, N.J. , May 30, 2018 (GLOBE NEWSWIRE) -- Emisphere Technologies , Inc. (OTCBB:EMIS) today announced that its non-prescription medical food product, Eligen B12, has earned the coveted “Amazon’s Choice” designation for being highly rated, fairly-priced, and available to ship immediately by
View HTML
Toggle Summary Emisphere Amends License Agreement with Novo Nordisk
Emisphere to Receive $7 Million Payment  ROSELAND, N.J., April 26, 2018 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB: EMIS ) today announced that it has amended its existing 2015 Development and License Agreement with Novo Nordisk A/S (NYSE: NVO ) for the development and
View HTML
Toggle Summary Emisphere Development Update
ROSELAND, N.J. , Feb. 22, 2018 (GLOBE NEWSWIRE) -- Novo Nordisk announced today the successful completion of the first phase 3a trial, PIONEER 1, with oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analog for the treatment of Type 2 diabetes, which utilizes Emisphere
View HTML
Toggle Summary Emisphere Transitions to Non-Reporting Public Company
ROSELAND, N.J. , Aug. 11, 2017 (GLOBE NEWSWIRE) -- The Board of Directors of Emisphere Technologies , Inc. (OTCBB:EMIS) announced today that the Company intends to voluntarily terminate its reporting obligations under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
View HTML
Toggle Summary Emisphere Reports First Quarter 2017 Financial Results
The Company to Host Conference Call Today at 8:30 AM ET
View HTML
Toggle Summary UPDATE -- Emisphere Announces First Quarter 2017 Earnings Conference Call
Conference Call/Webcast to be Held Friday, May 12, 2017, at 8:30 AM ET
View HTML
Toggle Summary Emisphere Announces First Quarter 2017 Earnings Conference Call
Conference Call/Webcast to be Held Friday, May 12, 2017, at 8:30 AM ET
View HTML
Toggle Summary Emisphere Reports Fourth Quarter and Full Year 2016 Financial Results
The Company to Host Conference Call Today at 8:30 AM ET
View HTML
Toggle Summary Emisphere Announces Fourth Quarter and Full Year 2016 Earnings Conference Call
Conference Call/Webcast to be Held Wednesday, March 29, 2017, at 8:30 AM ET
View HTML
Toggle Summary Emisphere Restructures Debt Agreements, Providing Greater Stability for Business Growth and Expansion
ROSELAND, N.J. , Dec. 09, 2016 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) announced today that it has reached agreement with MHR Fund Management LLC , and certain of its affiliated funds ("MHR") to waive certain of the terms of the Company's existing obligations under the loan
View HTML
Toggle Summary Emisphere Reports Third Quarter 2016 Financial Results
Management to Host Conference Call Today at 8:30 AM ET
View HTML
Toggle Summary Emisphere Announces Third Quarter 2016 Earnings Conference Call
Conference Call/Webcast to be Held Monday, November 14, 2016, at 8:30 AM ET
View HTML